Novo Nordisk AS (BSP:N1VO34) Investments And Advances : R$2,253 Mil (As of Mar. 2025)

View and export this data going back to 2020. Start your Free Trial

What is Novo Nordisk AS Investments And Advances?

Novo Nordisk AS's Investments And Advances for the quarter that ended in Mar. 2025 was R$2,253 Mil.

Novo Nordisk AS's quarterly Investments And Advances increased from Sep. 2024 (R$1,687 Mil) to Dec. 2024 (R$2,293 Mil) but then declined from Dec. 2024 (R$2,293 Mil) to Mar. 2025 (R$2,253 Mil).

Novo Nordisk AS's annual Investments And Advances increased from Dec. 2022 (R$1,003 Mil) to Dec. 2023 (R$1,192 Mil) and increased from Dec. 2023 (R$1,192 Mil) to Dec. 2024 (R$2,293 Mil).

Novo Nordisk AS Investments And Advances Historical Data

The historical data trend for Novo Nordisk AS's Investments And Advances can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Novo Nordisk AS Investments And Advances Chart

Novo Nordisk AS Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Investments And Advances

Get a 7-Day Free Trial

1,386.41

1,238.22

1,003.09

1,192.19

2,293.20

Novo Nordisk AS Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Investments And Advances	Get a 7-Day Free Trial															1,198.53	1,288.73	1,687.39	2,293.20	2,253.40

Novo Nordisk AS Investments And Advances Calculation

Investments And Advances includes all the non-current investments in affiliates, real estate, securities, etc.

Novo Nordisk AS Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Novo Nordisk AS (BSP:N1VO34) » Definitions » Investments And Advances

Comparable Companies

Traded in Other Exchanges

NONOF:USA NVO:USA NOVOB:Mexico NVO:Mexico 0TDD:UK NOVOBc:UK 0QIU:UK NOVO B:Denmark NOV:Germany NOV:Germany NOVA:Germany NOV:Germany NOV:Germany NOVA:Germany NVON:Canada NOV:Bulgaria NNO2:Austria

Address

Novo Alle 1, Bagsvaerd, DNK, 2880

Website

https://www.novonordisk.com

With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.

Novo Nordisk AS Headlines

No Headlines